402 related articles for article (PubMed ID: 36427310)
1. Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy.
Lei L; Huang D; Gao H; He B; Cao J; Peppas NA
Sci Adv; 2022 Nov; 8(47):eadc8738. PubMed ID: 36427310
[TBL] [Abstract][Full Text] [Related]
2. Hydrogel/nanoadjuvant-mediated combined cell vaccines for cancer immunotherapy.
Yang A; Bai Y; Dong X; Ma T; Zhu D; Mei L; Lv F
Acta Biomater; 2021 Oct; 133():257-267. PubMed ID: 34407475
[TBL] [Abstract][Full Text] [Related]
3. Advances in Cancer Vaccine Research.
Liu N; Xiao X; Zhang Z; Mao C; Wan M; Shen J
ACS Biomater Sci Eng; 2023 Nov; 9(11):5999-6023. PubMed ID: 37921277
[TBL] [Abstract][Full Text] [Related]
4. Biomineralized hydrogel DC vaccine for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment.
Huo W; Yang X; Wang B; Cao L; Fang Z; Li Z; Liu H; Liang XJ; Zhang J; Jin Y
Biomaterials; 2022 Sep; 288():121722. PubMed ID: 35963815
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicines for an Enhanced Immunogenic Cell Death-Based
Zhao C; Wang C; Shan W; Wang Z; Chen X; Deng H
Acc Chem Res; 2024 Mar; 57(6):905-918. PubMed ID: 38417027
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Vaccines for Cancer Immunotherapy.
Wang J; Mamuti M; Wang H
ACS Biomater Sci Eng; 2020 Nov; 6(11):6036-6052. PubMed ID: 33449675
[TBL] [Abstract][Full Text] [Related]
7. Programming Injectable DNA Hydrogels Yields Tumor Microenvironment-Activatable and Immune-Instructive Depots for Augmented Chemo-Immunotherapy.
Fan Y; Zhan M; Liang J; Yang X; Zhang B; Shi X; Hu Y
Adv Sci (Weinh); 2023 Oct; 10(29):e2302119. PubMed ID: 37541435
[TBL] [Abstract][Full Text] [Related]
8. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
[TBL] [Abstract][Full Text] [Related]
9. Vaccine-like nanomedicine for cancer immunotherapy.
Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
[TBL] [Abstract][Full Text] [Related]
10. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
11. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
Ni K; Luo T; Nash GT; Lin W
Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
[TBL] [Abstract][Full Text] [Related]
12. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response.
Wang QT; Liu YX; Wang J; Wang H
ChemMedChem; 2023 Jul; 18(13):e202200673. PubMed ID: 37088719
[TBL] [Abstract][Full Text] [Related]
13. Degradation-regulated architecture of injectable smart hydrogels enhances humoral immune response and potentiates antitumor activity in human lung carcinoma.
Duong HTT; Thambi T; Yin Y; Kim SH; Nguyen TL; Phan VHG; Kim J; Jeong JH; Lee DS
Biomaterials; 2020 Feb; 230():119599. PubMed ID: 31718883
[TBL] [Abstract][Full Text] [Related]
14. Tumor Microenvironment-Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade-Amplified Immune Response against Tumor Growth, Metastasis and Recurrence.
Gong S; Liang X; Zhang M; Li L; He T; Yuan Y; Li X; Liu F; Yang X; Shen M; Wu Q; Gong C
Small; 2022 Dec; 18(50):e2107061. PubMed ID: 36323618
[TBL] [Abstract][Full Text] [Related]
15. Current challenges for cancer vaccine adjuvant development.
Bowen WS; Svrivastava AK; Batra L; Barsoumian H; Shirwan H
Expert Rev Vaccines; 2018 Mar; 17(3):207-215. PubMed ID: 29372660
[TBL] [Abstract][Full Text] [Related]
16. Image-guided intratumoral immunotherapy: Developing a clinically practical technology.
Som A; Rosenboom JG; Chandler A; Sheth RA; Wehrenberg-Klee E
Adv Drug Deliv Rev; 2022 Oct; 189():114505. PubMed ID: 36007674
[TBL] [Abstract][Full Text] [Related]
17. Chemical Strategies to Boost Cancer Vaccines.
Li WH; Li YM
Chem Rev; 2020 Oct; 120(20):11420-11478. PubMed ID: 32914967
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
Butt AQ; Mills KH
Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
[TBL] [Abstract][Full Text] [Related]
19. Use of adjuvants for immunotherapy.
Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
[TBL] [Abstract][Full Text] [Related]
20. Biomaterials for vaccine-based cancer immunotherapy.
Zhang R; Billingsley MM; Mitchell MJ
J Control Release; 2018 Dec; 292():256-276. PubMed ID: 30312721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
